50. Nanni P, Pupa SM, Nicoletti G, De Giovanni C, Landuzzi L, Rossi I, et al. p185(neu) protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma. Int J Cancer 2000; 87:186-94; PMID:10861472; http:// dx.doi.org/10.1002/1097-0215(20000715)87:2,186:: AID-IJC5.3.0.CO;2-1 51. Cavallo F, De Giovanni C, Nanni P, Forni G, Lollini PL. 2011: the immune hallmarks of cancer. Cancer Immunol Immunother 2011; 60:319-26; PMID: 21267721; http://dx.doi.org/10.1007/s00262-010- 0968-0 52. Lollini PL, Nicoletti G, Landuzzi L, Cavallo F, Forni G, De Giovanni C, et al. Vaccines and Other Immunological Approaches for Cancer Immunoprevention. Curr Drug Targets 2011; 12:1957-73; PMID:21158706; http://dx.doi.org/10. 2174/138945011798184146 53. Calogero RA, Quaglino E, Saviozzi S, Forni G, Cavallo F. Oncoantigens as anti-tumor vaccination targets: the chance of a lucky strike? Cancer Immunol Immunother 2008; 57:1685-94; PMID:18286283; http://dx.doi.org/10.1007/s00262-008-0481-x 54. Holmgren L, Ambrosino E, Birot O, Tullus C, Veitonmäki N, Levchenko T, et al. A DNA vaccine targeting angiomotin inhibits angiogenesis and sup- presses tumor growth. Proc Natl Acad Sci U S A 2006; 103:9208-13; PMID:16754857; http://dx.doi.org/10. 1073/pnas.0603110103 55. Cavallo F, Calogero RA, Forni G. Are oncoantigens suitable targets for anti-tumour therapy? Nat Rev Cancer 2007; 7:707-13; PMID:17700704; http://dx. doi.org/10.1038/nrc2208 56. Wang X, Wang Y, Yu L, Sakakura K, Visus C, Schwab JH, et al. CSPG4 in cancer: multiple roles. Curr Mol Med 2010; 10:419-29; PMID:20455858; http://dx. doi.org/10.2174/156652410791316977 57. Chiarle R, Martinengo C, Mastini C, Ambrogio C, D’Escamard V, Forni G, et al. The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination. Nat Med 2008; 14:676-80; PMID:18469826; http://dx.doi.org/10.1038/nm1769 58. Lollini PL, Cavallo F, Nanni P, Forni G. Vaccines for tumour prevention. Nat Rev Cancer 2006; 6:204- 16; PMID:16498443; http://dx.doi.org/10.1038/ nrc1815 59. Curcio C, Di Carlo E, Clynes R, Smyth MJ, Boggio K, Quaglino E, et al. Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. J Clin Invest 2003; 111:1161- 70; PMID:12697735 60. Cavallo F, De Giovanni C, Nanni P, Forni G, Lollini PL. 2011: the immune hallmarks of cancer. Cancer Immunol Immunother 2011; 60:319-26; PMID:21267721; http://dx.doi.org/10.1007/s00262- 010-0968-0 61. Grange C, Lanzardo S, Cavallo F, Camussi G, Bussolati B. Sca-1 identifies the tumor-initiating cells in mammary tumors of BALB-neuT transgenic mice. Neoplasia 2008; 10:1433-43; PMID:19048122 62. Shultz LD, Ishikawa F, Greiner DL. Humanized mice in translational biomedical research. Nat Rev Immunol 2007; 7:118-30; PMID:17259968; http://dx.doi.org/ 10.1038/nri2017 63. Manz MG, Di Santo JP. Renaissance for mouse models of human hematopoiesis and immunobiology. Nat Immunol 2009; 10:1039-42; PMID:19767720; http:// dx.doi.org/10.1038/ni1009-1039 64. Adam J, Bellomo N. A survey of models for tumor- immune system dynamics. Boston: Birkhauser, 1997. 65. Lollini P-L, Motta S, Pappalardo F. Modeling tumor immunology. Math Mod Meth Appl Sci 2006; 16:1091-1124; http://dx.doi.org/10.1142/ S0218202506001479 66. Cavallo F, Offringa R, van der Burg SH, Forni G, Melief CJ. Vaccination for treatment and prevention of cancer in animal models. Adv Immunol 2006; 90:175- 213; PMID:16730264; http://dx.doi.org/10.1016/ S0065-2776(06)90005-4 67. Melani C, Chiodoni C, Forni G, Colombo MP. Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 trans- genic BALB/c mice suppresses immune reactivity. Blood 2003; 102:2138-45; PMID:12750171; http:// dx.doi.org/10.1182/blood-2003-01-0190 68. Park JM, Terabe M, Donaldson DD, Forni G, Berzofsky JA. Natural immunosurveillance against spontaneous, autochthonous breast cancers revealed and enhanced by blockade of IL-13-mediated negative regulation. Cancer Immunol Immunother 2008; 57:907-12; PMID:18004566; http://dx.doi.org/10. 1007/s00262-007-0414-0 69. Rolla S, Nicoló C, Malinarich S, Orsini M, Forni G, Cavallo F, et al. Distinct and non-overlapping T cell receptor repertoires expanded by DNA vaccination in wild-type and HER-2 transgenic BALB/c mice. J Immunol 2006; 177:7626-33; PMID:17114432 70. Spadaro M, Ambrosino E, Iezzi M, Di Carlo E, Sacchetti P, Curcio C, et al. Cure of mammary carcinomas in Her-2 transgenic mice through sequential stimulation of innate (neoadjuvant interleukin-12) and adaptive (DNA vaccine electroporation) immu- nity. Clin Cancer Res 2005; 11:1941-52; PMID: 15756020; http://dx.doi.org/10.1158/1078-0432. CCR-04-1873 71. Mayayo SL, Prestigio S, Maniscalco L, Rosa GL, Aricò A, Maria RD, et al. Chondroitin sulfate proteoglycan-4: A biomarker and a potential immunotherapeutic target for canine malignant melanoma. Vet J 2011; 190:e26- 30; PMID:21482159; http://dx.doi.org/10.1016/j.tvjl. 2011.02.020 72. Stevenson FK, Mander A, Chudley L, Ottensmeier CH. DNA fusion vaccines enter the clinic. Cancer Immunol Immunother 2011; 60:1147-51; PMID: 21644035; http://dx.doi.org/10.1007/s00262-011- 1042-2 www.landesbioscience.com OncoImmunology 325